Repligen Corporation faced a significant drop in its stock price, reflecting investor concerns over its financial performance.
Repligen Corporation (NASDAQ:RGEN) saw its stock fall by 7.80% in yesterday's trading session, closing at CA$177.23. This decline raises questions about the company's recent performance and future prospects.
Investor takeaway: Investors should be cautious about Repligen's financial health, as rising expenses and declining earnings per share could signal deeper issues within the company.
Advertisement
Repligen Corporation
RGEN.US
RGEN.US
Repligen Corporation
WealthAwesomeMarket cap
$10.00B
P/E
264.5x
52W high
$198.87
52W low
$100.99
1W change
-7.04%
Beta
1.05
Analyst Price Targets
Based on 19 analysts covering RGEN · as of Oct 1, 2026
Wall Street analysts forecast RGEN stock price to rise 7.0% over the next 12 months.
Consensus
Buy4.26 / 5.00
Avg. Target
C$189.70
+7.0% Upside
Previously C$189.48 on Sep 21, 2026
Current Price
C$177.23
Last close
Analyst Breakdown (19 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on RGEN's historical volatility
30-Day Vol
42.2%
Annualized
90-Day Vol
49.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$211.88
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$188.10 | C$162.59 – C$217.61 |
| 60 trading days | C$199.64 | C$162.45 – C$245.33 |
| 90 trading days | C$211.88 | C$164.61 – C$272.73 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
7.80% Drop in Stock Price
Repligen's stock price decline reflects growing investor skepticism regarding its financial stability and future earnings potential.
Bull case
Repligen has a solid lineup of bioprocessing technologies and has made strategic acquisitions that could strengthen its market position over time.
Bear case
The company's operating margins have worsened, and earnings per share have been on a steady decline, raising concerns about its ability to achieve sustainable growth.
Advertisement
Financial Performance Concerns
Repligen's stock performance yesterday was largely driven by investor worries about its financial health. The company's adjusted operating margin has dropped significantly, indicating that daily expenses are outpacing revenue growth. Over the past five years, Repligen has experienced a 3.8% annual decline in earnings per share, which is particularly concerning since stock prices typically follow EPS trends.
Market Reaction and Future Outlook
The sharp decline in Repligen's stock price reflects the market's reaction to its latest financial metrics. With a market cap of approximately $10 billion, investors are cautious about the company's ability to sustain growth given its recent performance. Analysts suggest that unless Repligen can reverse its trend of declining profitability, the stock may continue to face pressure in the near term.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
